Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- Keytruda/Ibrance Added to Pilot CEA Drug List, but There Won’t Be Price Tweaks
June 14, 2018
- Japan’s 1st Conditional OK Might Come This Autumn for Pfizer’s Next-Gen ALK Inhibitor Lorlatinib
June 13, 2018
- LDP’s Eto Study Group Submits Proposal to Health Minister
June 13, 2018
- PMDA to Promote Development of Next-Generation Drugs by Improving Its Science Level in Drug Evaluation
June 13, 2018
- MHLW to Study Ways to Increase Transparency of Process for Including Vaccines in Public Vaccination Programs
June 12, 2018
- MHLW’s New Anti-RA Measures Likely to Push Proper Use of Pricy Biologics
June 11, 2018
- MHLW Panel Gives Thumbs-Up for Entyvio, Official Nod Expected This Month
June 11, 2018
- Further Price Cuts for Off-Patent Drugs Erased from Draft Honebuto Paper
June 11, 2018
- Panel Members Positive about Going Digital on Package Inserts: HSC
June 11, 2018
- Govt Should Screen Drug Promotion Material, Scope of Information Provided: HSC Member
June 8, 2018
- Experts Support Plan to Seize Improperly Earned Revenue as in Diovan Case: HSC
June 8, 2018
- AMED Discloses Individual R&D Project Funding; 31 Receive Funding of Over 1 Billion Yen
June 7, 2018
- Deregulation Panel Pushes PMDA to Digitalize Process
June 6, 2018
- Reward Innovation to Solve Social Challenges: LDP Study Group
June 6, 2018
- Japan Eyes Economic Assessments for New Drug Listing: Draft Honebuto Paper
June 6, 2018
- Large Vessel Vasculitis to Be Added to Significant Adverse Reactions for G-CSF Preparations: MHLW
June 6, 2018
- Invoice Price Rates Decline Only for Long-listed Drugs at 3 Companies: MHLW Survey
June 4, 2018
- “Preclinical Registry” Will Accelerate Drug Discovery in Field of Dementia: AMED President
June 4, 2018
- AMED to Increase Transparency in Funding by Opening Up Research Database to Public
June 1, 2018
- Ex-Minister Shiozaki Holds Talks with PhRMA, EFPIA
June 1, 2018
ページ
Japan’s health and finance ministers agreed late last year to go ahead with an “off-year” drug price revision in FY2027,…
The Japanese healthcare sector is experiencing rapid growth, demanding a highly skilled and diverse workforce. However, finding and attracting the best talent in this competitive market presents significant challenges.Enter AI. With the rise of AI-powered tools, healthcare organizations can revolutionize…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…